GB0519303D0 - Chemo-immunotherapy method - Google Patents

Chemo-immunotherapy method


Publication number
GB0519303D0 GB0519303A GB0519303A GB0519303D0 GB 0519303 D0 GB0519303 D0 GB 0519303D0 GB 0519303 A GB0519303 A GB 0519303A GB 0519303 A GB0519303 A GB 0519303A GB 0519303 D0 GB0519303 D0 GB 0519303D0
United Kingdom
Prior art keywords
immunotherapy method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Application number
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica (UK) Ltd
Original Assignee
Oxford Biomedica (UK) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica (UK) Ltd filed Critical Oxford Biomedica (UK) Ltd
Priority to GB0519303A priority Critical patent/GB0519303D0/en
Publication of GB0519303D0 publication Critical patent/GB0519303D0/en
Application status is Ceased legal-status Critical


GB0519303A 2005-09-21 2005-09-21 Chemo-immunotherapy method Ceased GB0519303D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0519303A GB0519303D0 (en) 2005-09-21 2005-09-21 Chemo-immunotherapy method

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB0519303A GB0519303D0 (en) 2005-09-21 2005-09-21 Chemo-immunotherapy method
EP06779508.8A EP1931375B1 (en) 2005-09-21 2006-09-21 Chemo-immunotherapy method
CA 2622461 CA2622461A1 (en) 2005-09-21 2006-09-21 Chemo-immunotherapy method
ZA200802598A ZA200802598B (en) 2005-09-21 2006-09-21 Chemo-immunotherapy method
PCT/GB2006/003507 WO2007034188A2 (en) 2005-09-21 2006-09-21 Chemo-immunotherapy method
JP2008531780A JP2009508923A (en) 2005-09-21 2006-09-21 Methods of chemical immunotherapy
ES06779508.8T ES2626261T3 (en) 2005-09-21 2006-09-21 Chemoimmunotherapy Method
AU2006293659A AU2006293659C1 (en) 2005-09-21 2006-09-21 Chemo-immunotherapy method
CN 200680043514 CN101312741A (en) 2005-09-21 2006-09-21 Chemo-immunotherapy method
US12/052,710 US8133681B2 (en) 2005-09-21 2008-03-20 Chemo-immunotherapy method
US13/401,377 US20120213822A1 (en) 2005-09-21 2012-02-21 Chemo-immunotherapy method
JP2012093710A JP5940866B2 (en) 2005-09-21 2012-04-17 Chemoimmunotherapy methods

Publications (1)

Publication Number Publication Date
GB0519303D0 true GB0519303D0 (en) 2005-11-02



Family Applications (1)

Application Number Title Priority Date Filing Date
GB0519303A Ceased GB0519303D0 (en) 2005-09-21 2005-09-21 Chemo-immunotherapy method

Country Status (10)

Country Link
US (2) US8133681B2 (en)
EP (1) EP1931375B1 (en)
JP (2) JP2009508923A (en)
CN (1) CN101312741A (en)
AU (1) AU2006293659C1 (en)
CA (1) CA2622461A1 (en)
ES (1) ES2626261T3 (en)
GB (1) GB0519303D0 (en)
WO (1) WO2007034188A2 (en)
ZA (1) ZA200802598B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP2269618A1 (en) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
WO2007030668A2 (en) 2005-09-07 2007-03-15 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
WO2007130555A2 (en) * 2006-05-02 2007-11-15 Providence Health System Augmentation of immune response to cancer vaccine
AU2007272785A1 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2010039163A2 (en) * 2008-04-14 2010-04-08 Human Biomolecular Research Institute Chemical and biochemical adducts as biomarkers for organophosphate exposure
AU2009253539B2 (en) 2008-04-17 2014-03-20 Io Biotech Aps Indoleamine 2, 3-dioxygenase based immunotherapy
EP2313784B1 (en) 2008-07-15 2015-02-18 Oxford BioMedica (UK) Limited Immunotherapeutic method
US8114845B2 (en) 2008-08-25 2012-02-14 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
BRPI0917891A2 (en) * 2008-08-25 2015-11-24 Amplimmune Inc pd-1 antagonists and methods of using them
NZ592537A (en) * 2008-10-17 2012-07-27 Dana Farber Cancer Inst Inc Muc-1 cytoplasmic domain peptides as inhibitors of cancer
CN102665748A (en) 2009-05-27 2012-09-12 属肿瘤有限责任公司 Inhibition 0f inflammation using antagonists of MUC1
EP3409119A1 (en) * 2009-09-14 2018-12-05 SillaJen Biotherapeutics, Inc. Oncolytic vaccinia virus combination cancer therapy
WO2011066342A2 (en) * 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US8685928B2 (en) 2010-02-12 2014-04-01 Dana-Farber Cancer Institute, Inc. Antagonists of MUC1
US20130273092A1 (en) * 2010-10-22 2013-10-17 Trudeau Institute Uses of yersinia yope peptide, gene and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
CA2824277A1 (en) 2011-01-04 2012-07-12 Jennerex, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
KR101861416B1 (en) 2012-09-13 2018-05-25 유니베르시떼 드 제네브 Cell penetrating peptides
CN105039269A (en) * 2015-07-24 2015-11-11 北京鼎成肽源生物技术有限公司 Novel viral vaccine for treating non-small cell lung cancer and preparation method thereof
WO2018167486A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1423660A (en) * 1999-11-18 2003-06-11 牛津生物医学(英国)有限公司 Antibodies
EP2042598A1 (en) * 1998-11-18 2009-04-01 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
WO2004103271A2 (en) * 2003-04-18 2004-12-02 Norwood Immunology, Ltd. Disease prevention and vaccination prior to thymic reactivations
WO2002038612A2 (en) * 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
AU2003212170A1 (en) * 2002-03-25 2003-10-08 Technologies Biolactis Inc. Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
JP2005530716A (en) * 2002-03-27 2005-10-13 アメリカ合衆国 A method of treating cancer in humans
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
EP1578419A4 (en) * 2002-12-30 2008-11-12 3M Innovative Properties Co Immunostimulatory combinations
EP1597390A4 (en) * 2003-02-18 2006-12-27 Maxcyte Inc Loading of cells with antigens by electroporation
JP5015601B2 (en) * 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター Systems and methods for the treatment of cancer, including cancer of the central nervous system
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
US20100226931A1 (en) * 2004-06-24 2010-09-09 Nicholas Valiante Compounds for immunopotentiation
SE0402025D0 (en) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with super antigens in combination with another anti-cancer agent

Also Published As

Publication number Publication date
US8133681B2 (en) 2012-03-13
AU2006293659C1 (en) 2012-11-15
US20120213822A1 (en) 2012-08-23
EP1931375A2 (en) 2008-06-18
ES2626261T3 (en) 2017-07-24
JP5940866B2 (en) 2016-06-29
ZA200802598B (en) 2009-07-29
CN101312741A (en) 2008-11-26
JP2009508923A (en) 2009-03-05
AU2006293659B2 (en) 2012-04-05
US20090047307A1 (en) 2009-02-19
CA2622461A1 (en) 2007-03-29
AU2006293659A1 (en) 2007-03-29
EP1931375B1 (en) 2017-04-12
WO2007034188A2 (en) 2007-03-29
WO2007034188A3 (en) 2007-06-14
JP2012144563A (en) 2012-08-02

Similar Documents

Publication Publication Date Title
TWI317185B (en) Terminal-connecting means
DE502006001600D1 (en) Pyrazolylcarboxanilide
DE602006018441D1 (en) Arabinofuranosidasen
DE602006012366D1 (en) Oximester-photoinitiatoren
SI2194043T1 (en) Processes
GB0601961D0 (en) Method
DE602006013270D1 (en) Prrs-impfstoffe
DE602006021475D1 (en) Carbonylierungsverfahren
DE602006005477D1 (en) Imidazopyridinverbindungen
DE602006017073D1 (en) Aspartylproteasehemmer
DE602006018627D1 (en) Cholesterol-absorptionsinhibitor
GB0416310D0 (en) Method
GB0514593D0 (en) Process
DE602006016093D1 (en) Cyanoanthranilamidinsektizide
GB0424833D0 (en) Method
GB0513866D0 (en) Process
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
EP1864785A4 (en) Seterolithography method
GB0503836D0 (en) Method
GB0420061D0 (en) Method
DE602006015503D1 (en) Luftreinigeranordnung
HK1112724A1 (en) Photocosmetic method
ZA200802598B (en) Chemo-immunotherapy method
GB0511649D0 (en) Method
DE602006020169D1 (en) Differential-bogendraht

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)